Adverse reactions reported in ≥10% of patients who received LYNPARZA^® (with a difference of ≥5% vs placebo)¹

*Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03.¹
†Includes anemia, anemia macrocytic, and red blood cell count decreased.¹
‡Includes lymphocyte count decreased and lymphopenia.¹
§Includes abdominal discomfort, abdominal pain, abdominal pain upper, and abdominal pain lower.¹
||Includes dizziness and vertigo.¹

Fatal adverse reactions occurred in 6% of patients, including COVID-19 (3%) and pneumonias (0.5%)
Serious adverse reactions occurred in 39% of patients.¹

Serious adverse reactions reported in >2% of patients included anemia (6%), COVID-19 (6%), pneumonia (4.5%), pulmonary embolism (3.5%), and urinary tract infection (3%)¹

Venous thromboembolism (VTE), including severe or fatal pulmonary embolism (PE), occurred in patients treated with LYNPARZA. In the combined data of two randomised, placebo-controlled clinical studies (PROfound and PROpel) in patients with metastatic castration-resistant prostate cancer (N=1180), VTE occurred in 8% of patients who received LYNPARZA, including pulmonary embolism in 6%. In the control arms, VTE occurred in 2.5% including pulmonary embolism in 1.5%.¹

Laboratory abnormalities reported in ≥20% of patients in PROpel¹

*This number represents the safety population. The derived values in the table are based on the total number of evaluable patients for each laboratory parameter.¹

abi/pred, abiraterone plus prednisone or prednisolone; COVID-19, coronavirus disease 2019.

Reference: 1. LYNPARZA^® (olaparib). Prescribing information.